The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...
News Medical on MSN3d
Early diagnosis of Dementia with Lewy Bodies could be improved by cognitive profilingCognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...
Australian researchers say they have devised a first-of-its-kind tool that can accurately predict when a person will initially experience dementia symptoms based on their age and interview responses ...
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...
HealthDay on MSN23h
Dementia index shows validity for predicting age of onset of MCI, Alzheimer’s diseaseIn a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...
Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...
All 16 of Indiana’s designated senior care organizations — known as Area Agencies on Aging — are now required to have a ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Hosted on MSN19h
FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatmentEisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback